Available Technologies
# of Displayed Technologies: 10 / 12
Applied Category Filter (Click To Remove): Immunology, Autoimmune, Inflammation, Arthritis, Allergies
Novel Extracellular Vesicles Loaded with Anti-Inflammatory Agents
TS-065154 — , 2018-345 Revolutionary treatment for ARDS using novel extracellular vesicles loaded with Anti-Inflammatory Agents.
The Need
Acute Respiratory Distress Syndrome (ARDS) remains a significant healthcare challenge with high mortality rates and long-term morbidity. Despite advancements in supportive care, there’s an urgent need for pharmacologic treatments targeting the molecular mechanisms driving ARDS pathog…
- College: College of Medicine (COM)
- Inventors: Karpurapu, Manjula; Christman, John; Parinandi, Narasimham
- Licensing Officer: Willson, Christopher
Multimeric Notch ligands based on IgM-like fusion molecular structures for activation of ligand-specific Notch signaling
TS-064248 —
The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…
- College: OSU Wexner Medical Center
- Inventors: Dikov, Mikhail; Carbone, David; Goruganthu, Uttam Lakshmi Mounika; Tchekneva, Elena
- Licensing Officer: Willson, Christopher
An Orally Active, Selective Inhibitor of CD4+ T-Cell Activation That Blunts Left-Ventricular Remodeling and Improves Cardiac Function during Chronic Heart Failure
TS-057777 —
A novel orally-active drug molecule that can inhibit pathological CD4+ T-cells at clinically translatable doses and, blunts progressive cardiac dysfunction and left-ventricular (LV) remodeling during Heart Failure (HF).
HF afflicts ~6.5 million adults in US with 50% mortality in first 5 years. It has an estimated market size of $4.2B USD in US alone with a forecasted CAGR of 23% from 2018-2028. Current HF treatments are mostly aimed at alleviating symptoms rather than treatment, resulting in progressive cardiac d…
- College: College of Medicine (COM)
- Inventors: Bansal, Shyam; Gumina, Richard
- Licensing Officer: He, Panqing
Reduction in Incidence and Severity of Acute Graft-Versus-Host Disease (aGVHD) via CRISPR-Cas9 Deletion of the miR-155 Host Gene (MIR155HG) in Primary Human T Cells
TS-057739 —
CRISPR/Cas 9 mediated targeting of MIR155HG in primary human T cells creates genomic deletions that disrupt transcription of mature microRNA-155 (miR-155, a miR associated with inflammation). Applying this treatment to donor T cells prior to allogenic hematopoietic stem cell transplantation (allo-HSCT) when treating hematological malignancies and other primary bone marrow disorders can prevent the development of aGVHD in patients.
The Need
More than 8,000 patients receive allo-HSCT annually in the US alone as a cure for hematologic malignancies and other primary bone marrow disorders. However, the major barrier for the success of allo-HSCT is the high incidence of aGVHD and its associated morbidity and mortality. Acute GVHD…
- College: College of Medicine (COM)
- Inventors: Ranganathan, Parvathi; Garzon, Ramiro
- Licensing Officer: He, Panqing
Novel Natural Product Derivatives Targeting Chronic Diseases
TS-050220 — Novel natural products and derivatives thereof that exhibit potent in vitro and in vivo activity
The Need
Metabolic disorders such as type 2 diabetes are a major health concern that have impacted hundreds of millions of adults worldwide. Current pharmaceutical therapies for type 2 diabetes have been associated with adverse reactions including weight gain and increased risk of infection, liver …
- College: College of Pharmacy
- Inventors: Carcache de Blanco, Esperanza; Anaya Eugenio, Gerardo David; Eggers, Nicole
- Licensing Officer: He, Panqing
Identifying the level of lupus patients’ comprehension of their medication regimens and disease outcomes
TS-040132 — A questionnaire used to understand a patient’s comprehension of their personalized medication plan and the disease fluctuation of systemic lupus erythematous (SLE).
Systemic lupus erythematous (SLE) is an autoimmune disease in which the body’s immune system attacks healthy tissue in its own body. The disease has a prevalance of twenty to 150 cases per 100,000 individuals, and is more common in females than in men. This chronic disease has no cure, and s…
- College: College of Medicine (COM)
- Inventors: Meara, Alexa; Ardoin, Stacy; Peters, Ellen
- Licensing Officer: Taysavang, Panya
Treatment of Multiple Sclerosis with Small Molecule IL-6/STAT3 Inhibitors
TS-038701 —
Small-molecule prodrugs that target IL-6/STAT3 signaling pathway.
Multiple Sclerosis (MS), an unpredictable and disabling autoimmune disease affecting the central nervous system, is the leading cause of non-traumatic neurological disability in young adults. There have been important advances in MS therapy, such as drugs that slow the progression of the disease a…
- College: College of Medicine (COM)
- Inventors: Yang, Yuhong; Li, Chenglong; Racke, Michael
- Licensing Officer: He, Panqing
LNA Inhibitor Cocktail Therapy for Lupus
TS-037260 — A cocktail of locked nucleic acids inhibits the inflammatory response in a humanized murine model of lupus.
Systemic lupus erythematosus (SLE) is an orphan disease affecting approximately 5 in every 10,000 individuals. Despite its rare prevalence, this lifelong autoimmune disease has few effective targeted therapies. Current treatments are palliative using anti-inflammatory drugs or broad spectrum immun…
- College: College of Medicine (COM)
- Inventors: Jarjour, Wael; Valiente, Giancarlo; Young, Nicholas
- Licensing Officer: He, Panqing
Potential uses of IgG Fc for treating human diseases
TS-036778 —
Infectious diseases present a problem for treatment, with concerns for the overuse of antibiotic medicine, inefficiency of modern medicines, and a need in the market for novel technologies that will target and work in conjunction with the host immune system, rather than depending on external mecha…
- College: College of Medicine (COM)
- Inventors: Dai, Hongsheng; Caligiuri, Michael; Yu, Jianhua
- Licensing Officer: Taysavang, Panya
Immunomodulating agents engineered from Notch receptor ligand extracellular domains
TS-036760 — Immunomodulating agents have been engineered from Notch receptor ligand extracelluar domains. These are useful for stimulating the immune system.
The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…
- College: College of Arts & Sciences
- Inventors: Magliery, Thomas; Carbone, David; Dikov, Mikhail; Long, Nicholas; Sullivan, Brandon; Tchekneva, Elena
- Licensing Officer: Dahlman, Jason "Jay"
